Apyx Medical Corporation provided earnings guidance for the full year 2022. For the year, the company expects Total revenue in the range of $50.0 million to $63.0 million, representing growth of 3% to 30% year-over-year, compared to total revenue of $48.5 million for the year ended December 31, 2021. Net loss attributable to stockholders in the range of $21.1 million to $12.1 million, compared to net loss attributable to stockholders of $15.2 million for the year ended December 31, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | -1.40% | 0.00% | -46.18% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.18% | 49.54M | |
-5.51% | 182B | |
+2.33% | 111B | |
-3.62% | 68.48B | |
+1.52% | 49.69B | |
+8.06% | 44.46B | |
+2.33% | 40.67B | |
+23.35% | 31.22B | |
+0.67% | 26.09B | |
+15.30% | 25.32B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Full Year 2022